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Abstract
Background Survivin is a member of the inhibitor of an apoptosis protein family that has been shown to inhibit apoptosis,
promote cell proliferation and enhance angiogenesis. In this study, the survivin protein expression in normal, colon polyp, and
adenocarcinoma tissues was investigated.
Methods Immunohistochemical staining for nuclear survivin was carried out on 45 normal colon tissue samples, 38 samples of a
colonic polyp, and 37 cases of colon adenocarcinoma operated by colonoscopy or colectomy. The percentages of cells that
expressed survivin were classified qualitatively into four categories (0, 1+, 2+, and 3+) based on the intensity of staining and the
percentage of cells. An area of samples with colon polyp diagnosis or colon adenocarcinoma that had no microscopic pathology
was considered as normal tissues.
Results Survivin protein expression was negative in all cases of normal colon tissue samples while it was expressed in 31
out of 38 colon polyp specimens (81.5%) and in 35 out of 37 (94.5%) colon adenocarcinoma samples. Amount of
expression in the colon adenocarcinoma (p < 0.001) was significantly higher than the amount of expression in the colon
polyp. There was not a significant correlation between the survivin protein expression and the low and high grade
adenocarcinoma (p = 0.874).
Conclusions Survivin protein was not expressed in normal colon tissues and its amount was higher in the colonic adenocarci-
noma compared to the colon polyp. Due to the variations in the intensity of expression in colon polyp (changing from negative to
+ 3), this marker cannot be used for differentiating the polyp from the adenocarcinoma.
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Introduction
The colon carcinoma is the third most common cancer among
men and women, and is also the second leading cause of
cancer death. Men and women are affected equally, with an
average age of 62 years. In a microscopic examination, ade-
nocarcinoma of the colon shows a wide range of views, which
are highly differentiated from neoplasia to various anaplastic
tumors [1]. The growth and progression of the tumor in the
large intestine depend on the balance between the two factors
of cell proliferation and cell death or apoptosis [2] (Fig. 1).
Apoptosis is a cell death pathway in which lethal cells
(tumor cells or DNA-damaged cells) activate enzymes that
destroy DNA and its nuclear and cytoplasmic proteins and
cell membranes. Phagocytic cells remove apoptotic cells be-
fore leakage of cell contents [3].
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Apoptosis is initiated and regulated by a cascade of mo-
lecular events. Two protein families are involved in the
regulation of apoptosis mechanisms: pro-apoptotic protein
family and anti-apoptotic protein family or inhibitors of
apoptosis proteins (IAP). Since planned death of cells can
be considered as one of the defense mechanisms of the
human body against cancer, the expression of unregulated
anti-apoptotic proteins can lead to elongation of cells; thus,
distort mutations and ultimately cause the occurrence and
development of cancer [4].
Survivin is an inhibitor of apoptosis that exerts its role in
cell proliferation by inhibiting cell-mediated cell death or en-
hancing mitosis [4, 5]. The survivin gene is located at position
25 on the long arm of chromosome 17, which results in pro-
tein coding of 142 amino acids. In contrast to other apoptosis-
inhibiting proteins that have a ring-like portion at the end of
their carboxylate, survivin has a helical portion of the α-helix
similar to that found in microtubule-associated proteins, and
with this section, the end of C on speaks to tubulin. Thus, the
microtubules of the channel are split and prevent apoptotic
cascades [6, 7].
Survivin is the smallest member of the family of IAP
[8]. This protein restricts apoptosis by controlling caspase
and has the highest expression in the G2/M phase of cell
division, which is essential for the progression of mitosis
[8, 9].
During the mitosis process, survivin is a component of
the chromosomal transfer protein of chromosomal passive
proteins (CPPs), which remains complex and essential for
biorientation and cell division [10]. Survivin is expressed
in the nucleus and cytoplasm of tumor cells [11].
Nuclear survivin appears to promote cell proliferation and
the cytoplasmic survivin inhibits apoptosis [12]. Recent evi-
dence suggests that the placement of survivin in the cell (nu-
clear or cytoplasmic) may be associated with prognosis
[13–15].
In this study, by examining the immunomodulatory layer,
the paraffin blocks of the survivin colon samples in the colon
tissue were examined, and the colon; colon and adenocarci-
noma polypeptides were evaluated on the basis of histopathol-
ogy of the colon. Samples with adenocarcinoma diagnosis of
protein expression are compared with malignancy after grad-
uating from American Pathologist College [16]. The relation-
ship between age and sex of patients with survivin protein
incidence is also investigated.
Materials and Methods
This case-control study was performed on the samples sent to
the Department of Pathology at Shahid Beheshti Hospital in
2014–2015. Adenocarcinoma samples were counted and nor-
mal samples were randomly selected and examined. The un-
derlying data of the samples were extracted from the database
and patient records. Colon tissue specimens that had under-
gone a colonoscopy or colectomy were sent to the Department
Fig. 1 Frequency of age
distribution of patients in the three
groups
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of Pathology at Shahid Beheshti Hospital. Paraffin blocks and
tissue sections with a thickness of 5 μmwere prepared accord-
ing to standard protocols. A number of slides were stained in a
similar manner to the hematoxylin-eosin method and the same
slides were immunohistochemically stained according to stan-
dard formulations. Briefly, the fabric layer was held at 60 °C
for 2 h. For rehydration, the layers were then added sequen-
tially to ethanol and distilled water. To eliminate the activity of
endogenous peroxidases, the slides were placed in a freshly
prepared 3% hydrogen peroxide solution for 20 min. Then, it
was washed twice and every 5 min with phosphate buffer
saline buffer.
The antigen-retracted slides were then placed in a vessel
containing pH = 6 citrate buffer for 10 min in an autoclave at
134 °C and a pressure of 1.5–2 bar. Then, let the screws cool
(about 20 min) then wash with distilled water [17–19].
In the next step, the anti-survivin antibody was prepared
and added for 1 h. Then, the PBS buffer was washed three
times and every 5 min. Then, we added the secondary anti-
body to the sections for about half an hour at room tempera-
ture. At this stage, washing was done with PBS buffer
[20–22].
At this stage, the sections were placed in a DAB dilution
solution for 10 min (DAB ratio = 1.9, with DAB saturation
buffer) and then washed with water. The background was
then stained with hematoxylin for 1 min and then washed.
For dehydration of slides, absolute alcohol and xylol solu-
tions were used. Finally, the limbs were mounted and ready
f o r e x am in a t i on by op t i c a l m i c r o s copy [ 23 ] .
Histopathological diagnosis was determined based on
hematoxylin-eosin stained slides and parts of the sample
without pathology were considered as normal samples
[24–26].
The stained slides were immunohistochemically examined
and classified into positive and negative categories, and pos-
itive samples were classified according to the color intensity
from + 1 to + 3 [27] (Fig. 2):
& Negative or weakly stained samples in less than 10% of
the cells: negative
& Poor to moderate staining in 10–29% of the cells: a posi-
tive (+ 1)
& Medium to strong dye in 30–49% of the cells: two positive
(+ 2)
& Extreme color fastness is about 50% of the cells: three
positive (+ 3)
According to the instructions, the cervical squamous
cell carcinoma antibody kit was used as a positive control
and the normal cervical tissue was used as a negative con-
trol. All staining stages of hematoxylin-eosin and
Fig. 2 Negative, less than 10% of the epithelial cells were poorly colored (a); positive, 29–10% poor to moderate coloration in epithelial cells (b);
positive, 49–30% moderate to severe coloration in epithelial cells (c); positive, more than 50% of the epithelial cells were stained strongly (d)
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immunohistochemistry were simultaneous and similar to
those of the samples tested with positive control and neg-
ative control.
The obtained data were recorded for each sample including
histopathology, tumor grade, positive or negative immunohis-
tochemistry, and color intensity, and then analyzed using sta-
tistical information on the age of the patient.
Statistical Analysis
After collecting the required data, the results were analyzed
with the software SPSS 24. The Kolmogorov-Smirnov test
was used to evaluate the normality of the data. In this study,
parametric tests such as mean analysis variance analysis, chi-
square test [28], and correlation tables were used to investigate
the independence of multilevel variables and compare
survivin protein positivity in the groups studied. Kruskal’s
nonparametric test is also consistent with nonparametric
ANOVA analysis in cases where data is abnormal. In this
study, the P value (the value of the test error value) is 0.05
with a confidence level of 95%.
Results
The study was performed on 120 colon tissue samples. There
were 45 cases of normal colon tissue, 38 cases of polyps, and
37 cases of colon adenocarcinoma (Table 1).
As can be seen from the above table, there is no significant
difference in the sex ratio between the three groups.
The mean age of patients in the normal group was 63 years,
the 58-year-old polyp group, and the colon adenocarcinoma
group 63 years (Table 2).
With regard to the standardization of data for all three
groups, we used ANOVA for comparison. The probability of
the above table is 0.298 and is greater than 0.05. Therefore, the
hypothesis of the mean-graded elderly was included in the
colon, polyps, and triple colon adenocarcinoma of the normal
colon (Table 3).
Regarding the nonnormalization of survivin data in all
three groups, Kruskal-Wallis test is used to determine the non-
parametric equation of variance analysis and with the lower
probability of a significant probability of 0.05 in the table
above, the assumption of the equality of the meanings in the
three groups is rejected. Survivin levels were significantly
different in adenocarcinoma, polyps, and healthy patients.
The mean that survivin protein expression in adenocarcinoma
is 2.05, polyp 1.37, and normal tissue was zero (Table 4).
Survivin protein expression expressed in terms of the in-
tensity of coloration of the epithelial cells nucleus was as
follows:
Of the 45 normal colon tissues, the dye levels were less
than 10% of the epithelial cells in all cases, and 100% of the
cases were reported negative.
In 38 samples of colon polyp, 7 cases (18.4%) were nega-
tive, 14 cases (36.8%) were positive 1, 13 cases (34.2%) were
positive 2, and 4 cases (10.5%) were positive 3. Out of 37
cases of adenocarcinoma of the colon, 2 cases (5.4%) were
Table 1 Frequency of sample
distribution by gender Sex Group Chi-square test
Adenocarcinoma Polyp Normal
Count Column N % Count Column N % Count Column N %
Male 19 51.4% 20 52.6% 25 55.6% 0.925
Female 18 48.6% 18 47.4% 20 44.4%
Total 37 100.0% 38 100.0% 45 100.0%
Table 2 Frequency of distribution of samples in three groups based on
the age of patients and distribution of survivin level
ANOVA test Groups P
value
Adenocarcinoma
colon
Polyp Normal
colon
Age Average 63.24 58.45 62.84 0.298
Standard
deviation
15.64 13.69 15.41
Table 3 Serivine level distribution in the three study groups
Kruskal-Wallis test Groups P value
Adenocarcinoma
colon
Polyp Normal
colon
Survivin Average 2.05 1.37 0.00 < 0.001
Standard
deviation
0.91 0.91 0.00
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negative, 8 cases (21.6%) were positive 1, 13 cases (35.1%),
positive 2, and 14 cases (37.8%) were positive 3 (Table 4).
To examine the impact of the level of survivin levels on
groups, we use a cross-sectional table assuming the indepen-
dence of the two survivin and grouping variables. At a prob-
ability value of 0.05, the assumption is zero. Survivin grading
showed a significant difference in adenocarcinoma, polyp,
and normal groups (p < 0.001).
The result of our research indicated that survivin protein
level did not show significant differences in adenocarcinoma
severity (p = 0.874) (Table 5).
Based on the above table, the survivin level is significant in
both adenocarcinoma and normal groups (p < 0.001) (Table 6).
Based on the above table, it can be concluded that the level
of survivin is significant in both polyp and normal groups
(p < 0.001) (Table 7).
According to the above table, the survivin protein profile in
adenocarcinoma and polyp groups also showed that this dif-
ference is quite significant (p = 0.018) (Table 8).
Discussion
Like other tumors, the growth and development of tumors in
the colon depends on the balance between cell proliferation
and planned cell death or apoptosis. Uncontrolled expression
of anti-apoptotic proteins can result in prolonged cell life,
leading to mutational changes and ultimately to the onset
and progression of cancer [2]. Survivin is an inhibitor of apo-
ptosis that plays a role in cell proliferation by controlling cell-
based cell death or mitosis.
Survivin protein expression in colon tissue was
immunohistochemically studied in this study. Colonial adeno-
carcinomas, colon polyps, and normal colon tissue were com-
pared for survivin protein expression, and in adenocarcinoma
colon samples, survivin protein expression was ranked by the
College of American Pathologist. The relationship between
age and sex of patients with survivin protein was also
investigated.
In this study, normal fetuses were used to examine normal
tissue along with polyps and adenocarcinoma samples. As
with Shariat and colleagues, normal tissue was used in con-
junction with adenocarcinoma samples [29]. In some studies,
autopsies have been used to obtain normal tissue [30], but our
access to autopsy specimens was not possible.
The results of this study were consistent with the standard
expression of survivin protein in normal colon tissue similar to
previous studies in which normal colon samples were obtain-
ed by autopsy [9, 27]. This study also showed that survivin
protein is not expressed in the nucleus of normal gland epi-
thelial cells. According to the results, nuclear survivin protein
was not expressed in normal colon tissue. In polyps and
Table 4 The frequency of
survivin grading distribution in
the three study groups
Survivin Group Chi-square test
Adenocarcinoma Polyp Normal
Count Column N % Count Column N % Count Column N %
.00 2 5.4% 7 18.4% 45 100.0% < 0.001
1.00 8 21.6% 14 36.8% 0 .0%
2.00 13 35.1% 13 34.2% 0 .0%
3.00 14 37.8% 4 10.5% 0 .0%
Total 37 100.0% 38 100.0% 45 100.0%
Table 5 Comparison of serovinin protein expression in different colon
adenocarcinoma severities
Survivin Cancer grade P value
low High
Count Column N % Count Column N %
.00 1 4.2% 1 7.7 0.874
1.00 6 25.0% 2 15.4
2.00 9 37.5% 4 30.8
3.00 8 33.3% 6 46.2
Total 24 100.0% 13 100.0
Table 6 Comparison of survivin grading in adenocarcinoma and
healthy samples
Survivin Group P value
Adenocarcinoma Normal
Count Column N % Count Column N %
.00 2 5.4% 45 100.0 < 0.001
1.00 8 21.6% 0 .0
2.00 13 35.1% 0 .0
3.00 14 37.8% 0 .0
Total 37 100.0% 45 100.0
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adenocarcinomas, it was expressed that the expression rate in
polyps was 81.6% and adenocarcinoma 94.6%.
In the current study, survivin protein was positively
expressed in polyp samples at different rates from negative
to 3. In most cases, the level of expression was positive and
only in 10.5% of the cases was the expression greater than
50% of the epithelial cells of the glands and was given as 3
positive. In the adenocarcinoma of the colon, the expression
varied from negative to 3 positive. Negative specimens
consisted of only 4.5%, and most cases reported survivin pro-
tein levels at 3%.
In this study, the survivin protein expression in colon ade-
nocarcinoma was higher than the polyp. However, there was
no significant relationship with malignancy. In a study by
Michiko Shintani et al., there was no significant association
between survivin incidence and clinicopathologic parameters
[31]. However, in a study by Adamkov et al., out of 113
samples of colon carcinoma, 47 samples expressed survivin
protein and the survivin positivity was proportional to gradient
elevation [23].
The study found that the likelihood of cancer compared to
the polyp increases in survival, so the increase in survival per
unit increases the likelihood of cancer by 2.23-fold, and this
relationship is quite significant (p = 0.005), In this study, the
age of patients with survivin protein expression was not sig-
nificantly correlated.
Due to the limited sample size, we did not have a signifi-
cant relationship between the severities of adenocarcinoma.
Also, due to the nature of survivin protein determination, it
was not possible to carry out a quantitative investigation be-
tween the adenocarcinoma with normal group and normal
polyp group.
Based on this study, if the pathology between the polyps
and the adenocarcinoma is uncertain, the level of survivin may
increase the likelihood of a correct diagnosis. With increasing
survivin level, the adenocarcinoma increases.
Recently, survivin gene targeting has been studied in can-
cer therapy, and in some studies, inhibition of survivin in gene
transcription and translation or demyelination of survivin has
been used in preclinical or clinical trials [8].
Conclusion
This study examines the expression of survivin protein in
adenocarcinomas and colonic polyps, and it appears that ex-
pression of this protein in adenocarcinoma colon samples may
be used as a biomarker for better patient care in the future.
However, extensive studies and clinical trials are required in
this context.
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Table 7 Comparison of survivin grading in two groups of polyps and
normal samples
Survivin Group P value
Polyp Normal
Count Column N % Count Column N %
.00 7 18.4% 45 100.0 < 0.001
1.00 14 36.8% 0 .0
2.00 13 34.2% 0 .0
3.00 4 10.5% 0 .0
Total 38 100.0% 45 100.0
Table 8 Comparison of survivin grading in adenocarcinoma and polyp
samples
Survivin Group P value
Polyp Adenocarcinoma
Count Column N % Count Column N %
.00 7 18.4% 2 5.4 0.018
1.00 14 36.8% 8 21.6
2.00 13 34.2% 13 35.1
3.00 4 10.5% 14 37.8
Total 38 100.0% 37 100.0
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